基于成本-效果分析法评价人工肝治疗肝衰竭的经济学疗效  

Evaluation of the Economic Efficacy of Artificial Liver Support System in the Treatment of Liver Failure Based on Cost-effectiveness Analysis*

作　　者：曾雨雨 谢能文[2] 熊云逢 徐意珍 甘达凯 熊墨龙[1,2] ZENG Yuyu;XIE Nengwen;XIONG Yunfeng;XU Yizhen;GAN Dakai;XIONG Molong(Third Clinical Medical College of Nanchang University;Department of Severe Liver Disease,Infectious Diseases Hospital Affiliated to Nanchang University,Nanchang 330002,Jiangxi,China)

机构地区：[1]南昌大学第三临床医学院 [2]南昌大学附属感染病医院重症肝病科,江西南昌330000

出　　处：《现代诊断与治疗》2023年第24期3641-3644,共4页Modern Diagnosis and Treatment

基　　金：2021年度江西省卫生健康委科技计划项目(项目编号202140131)。

摘　　要：目的比较标准内科治疗与标准内科治疗联合人工肝治疗肝衰竭的经济效果,为临床肝衰竭治疗方案的选择提供参考和作出合理决策。方法收集2022年1月至2023年1月我院重症肝病科住院的肝衰竭患者的病历资料,根据其治疗过程中是否使用人工肝治疗分为标准内科治疗组(SMT组)与标准内科治疗联合人工肝治疗组(ALSS组),统计患者的住院总费用,记录患者的90 d疗效,运用成本-效果分析法对两种治疗方案进行分析。结果ALSS组与SMT组的平均住院总费用分别为62881.2元和51226.2元;两组90 d总有效率分别为76.3%和52.4%,差异有统计学意义(P<0.05);两组成本-效果比分别为82396.1元和97795.5元。结论人工肝治疗可提高肝衰竭患者的临床疗效,相较于标准内科治疗具有更高的经济效益值。Objectives To compare the economic effects of standard medical treatment and standard medical treatment combined withartificial liver support system in the treatment of liver failure,so as to provide reference and reasonable decisionsfor the selection of clinical treatment schemes for liver failure.Methods The medical records of patients with liver failure hospitalized inthe Department of Severe Liver Disease from January 2022 to January 2023 were collected.According to whether artificial liver support system was used in the course of treatment,the patients were divided into the group of standard medical treatment(group SMT)and group of standard medical treatment combined with artificial liver support system(group ALSS).The total hospitalization cost of the patients was counted,and the 90-day efficacy of the patients was recorded.Results The average total hospitalization cost of ALSS groupand SMTgroup were 62881.2 yuan and 51226.2 yuan,respectively.The 90-day total effective rates of the two groups were 76.3%and 52.4%,respectively,and the difference was statistically significant(P<0.05).The cost-effectiveness ratios of the two groups were 82396.1 yuan and 97795.5 yuan,respectively.Conclusions Artificial liver support system can improve the clinical efficacy of patients with liver failure,and has higher economic benefits than standard medical treatment.

关 键 词：肝衰竭 人工肝 成本-效果分析 

分 类 号：R575.3[医药卫生—消化系统]